Qube Research & Technologies LTD Macrogenics Inc Transaction History

Qube Research & Technologies LTD

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$9.77 - $21.47 $2.11 Million - $4.64 Million	215,937 Added 706.92%	246,483 $3.63 Million
Q4 2023 Feb 13, 2024	BUY	$4.48 - $10.11 $136,846 - $308,820	30,546 New	30,546 $293,000
Q2 2022 Aug 15, 2022	BUY	$2.25 - $9.99 $272,610 - $1.21 Million	121,160 Added 218.11%	176,710 $521,000
Q1 2022 May 09, 2022	BUY	$8.12 - $16.9 $209,398 - $435,817	25,788 Added 86.65%	55,550 $489,000
Q4 2021 Feb 01, 2022	BUY	$15.91 - $21.88 $152,449 - $209,654	9,582 Added 47.48%	29,762 $478,000
Q3 2021 Nov 12, 2021	BUY	$19.74 - $28.7 $398,353 - $579,166	20,180 New	20,180 $423,000

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.